Hiroyuki Miura

Hiroyuki Miura

Auto-generated profile, based on publicly available information

Hiroyuki Miura

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
MCMisato Chimura
Misato Chimura
SKShinji Koba
Shinji Koba
YSYasushi Sakata
Yasushi Sakata
TITakayuki Ise
Takayuki Ise
HMHiroyuki Miura
Hiroyuki Miura
TTTatsunori Taniguchi
Tatsunori Taniguchi
Introduction Cardiac rehabilitation (CR) is strongly recommended as a medical treatment to improve the prognosis and quality of life of patients with heart failure (HF); however, participation rates in CR are low compared with other evidence-based treatments. One reason for this is the geographical distance between patients’ homes and hospitals. To address this issue, we developed an integrated telerehabilitation platform, RH-01, for home-based CR. We hypothesised that using the RH-01 platform for home-based CR would demonstrate non-inferiority compared with traditional centre-based CR. Methods and analysis The E-REHAB trial aims to evaluate the efficacy and safety of RH-01 for home-based CR compared with traditional centre-based CR for patients with HF. This clinical trial will be conducted under a prospective, randomised, controlled and non-inferiority design with a primary focus on HF patients. Further, to assess the generalisability of the results in HF to other cardiovascular disease (CVD), the study will also include patients with other CVDs. The trial will enrol 108 patients with HF and 20 patients with other CVD. Eligible HF patients will be randomly assigned to either traditional centre-based CR or home-based CR in a 1:1 fashion. Patients with other CVDs will not be randomised, as safety assessment will be the primary focus. The intervention group will receive a 12-week programme conducted two or three times per week consisting of a remotely supervised home-based CR programme using RH-01, while the control group will receive a traditional centre-based CR programme. The primary endpoint of this trial is change in 6 min walk distance. Ethics and dissemination The conduct of the study has been approved by an institutional review board at each participating site, and all patients will provide written informed consent before entry. The report of the study will be disseminated via scientific fora, including peer-reviewed publications and presentations at conferences. Trial registration number jRCT:2052200064.

2 September 2026 in European Heart Journal Open
Verified
Journal Article
Open access
HAHirohiko Aikawa
Hirohiko Aikawa
KMKota Murai
Kota Murai
YKYu Kataoka
Yu Kataoka
YNYuriko Nakaoku
Yuriko Nakaoku
SOSoshiro Ogata
Soshiro Ogata
TNTeruo Noguchi
Teruo Noguchi
Aims: Fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPRs) frequently yield discordant results in clinical practice, yet the mechanisms underlying this mismatch remain uncertain. Plaque composition has been suggested to influence FFR, raising the possibility that discordance reflects the features of lipid-rich plaque (LRP). This study aimed to investigate whether physiological discordance between FFR and NHPR is associated with increased lipid burden. Methods and results: We retrospectively analysed 217 intermediate coronary lesions from 189 patients who underwent FFR, NHPR, and near-infrared spectroscopy with intravascular ultrasound imaging. Lesions were classified using established cut-offs for FFR (0.80) and NHPR (0.89). Lipid burden was quantified by the maximum lipid core burden index within any 4-mm segment (maxLCBI4mm). Lipid-rich plaque was defined as maxLCBI4mm > 400. The clinical endpoint was 3-year target vessel failure (TVF). Physiological discordance occurred in 24.0% of lesions, predominantly as an FFR+/NHPR− pattern (19.8%). FFR was independently associated with maxLCBI4mm [β, 65.2; 95% confidence interval (CI), 29.0–101.5; P < 0.001], whereas NHPR was not (β, 16.5; 95% CI, −15.9 to 49.0; P = 0.316). The FFR+/NHPR− group demonstrated the highest maxLCBI4mm (525 ± 201) and the greatest prevalence of LRP (65.1%; both P < 0.001). In multivariable analysis, the FFR+/NHPR− pattern independently predicted LRP [adjusted odds ratio, 6.12; 95% CI, 1.20–31.28; P = 0.030]. TVF occurrences did not differ significantly across physiological groups. Conclusion: FFR+/NHPR− lesions exhibit markedly greater lipid burden, suggesting that hyperaemia-based indices better capture plaque vulnerability than resting physiology. This pattern may serve as a marker of plaque vulnerability, suggesting that deferral of FFR+/NHPR− lesions could warrant caution given their higher lipid burden.